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1. Introduction 
Both pediatric and adult malignant intraocular ocular tumors are often treated with external 
beam radiation or brachytherapy.  Because the lens is the most radiosensitive ocular 
structure, cataracts are a common occurrence after such treatments.  Some studies report up 
to an 87% occurrence of cataracts within 3 years in retinoblastoma patients treated with 
external beam radiation (Blach et al., 1996; Fontanesi et al., 1996).  In the Collaborative 
Ocular Melanoma Study, the largest multicenter prospective randomized trial ever 
performed for uveal melanoma patients, 83% of patients had developed cataracts by 5 years 
post-treatment (Collaborative Ocular Melanoma Study Group, 2007).  Because many 
patients treated for intraocular tumors survive for extended periods and have the capacity 
for excellent vision, cataract surgery is an important part of the treatment algorithm for 
these patients.  However, this group of patients poses a unique set of surgical challenges not 
present in standard cataract patients.  In this chapter, we will review the incidence, surgical 
techniques, visual and anatomic outcomes, and complications for this unique group of 
patients. 
2. Cataracts in retinoblastoma patients  
2.1 Epidemiology 
2.1.1 Incidence 
Cataract is a well-known complication after radiation to the eye after all forms of radiation.  
Many studies have indicated that after external beam radiation therapy, cataracts can 
develop after doses as low as 2 Gy (Dynlacht, 2006; Gordon, 1995).  For over 100 years, 
external beam radiation has been used to treat retinoblastoma because in certain cases, it can  
achieve tumor control and enable retention of vision when other treatment modalities have 
failed (Chodick et al., 2009).  Although other treatment modalities such as chemotherapy 
and laser are more commonly used for retinoblastoma patients at the present time, external 
beam radiation is still used as salvage therapy in advanced cases.  Furthermore, many 
patients who received external beam radiation in the past are still under the care of 
ophthalmic oncologists and are currently in need of or will need cataract surgery in the 
future.  Chodick et al. examined the records of a series of 753 patients who were diagnosed 
with retinoblastoma from 1914 to 1984.  Only one patient who had not had radiotherapy had 
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cataract surgery while 51 cataract surgeries were performed in patients who had had 
radiation.  Overall, Kaplan-Meier analysis demonstrated that after 40 years of follow-up, 
77% of eyes with 2 or 3 radiotherapy treatments underwent cataract surgery.  The estimated 
survival time to cataract surgery in eyes that did not undergo radiation was 71.7 years 
compared to 50.8 years and 31.6 years for eyes treated with one and 2 or 3 radiotherapy 
treatments, respectively.  Of note, many patients in this study underwent older forms of 
treatment with more radiation scatter such as orthovoltage radiation and cobalt plaques.  
Nonetheless, the incidence of cataracts requiring cataract surgery in retinoblastoma 
survivors was high and underscored the necessity for ongoing ophthalmic follow-up in 
these patients. 
2.1.2 Risk factors 
In the study by Chodick et al., the clinical risk factors that contributed to cataract 
development requiring cataract surgery were: increased number of external beam radiation 
treatments, diagnosis of retinoblastoma after the first year of life (versus earlier), and 
radiation dose.  No other studies published up until this point have had extended follow-up 
or enough power to assess the risk factors for cataract development adequately. 
2.2 Visual and anatomic results 
2.2.1 Visual results 
There have been several studies examining the visual outcomes in retinoblastoma survivors 
who have undergone cataract surgery (Table 1). 
The data from Table 1 suggests that visual outcomes in these patients can be surprisingly 
excellent.  In particular, the studies by Miller et al. (2005), Payne et al. (2008), and Hoehn et 
al. (2010) reported good visual results and no major complications.  Patients in this 
population have many other reasons to have poor visual outcomes including tumor 
involvement of the macula, radiation retinopathy, progressive retinal scarring from laser or 
cryotherapy treatments, and amblyopia.   
2.3 Surgical approach and complications  
Controversies in pediatric cataract management include the surgical approach, management of 
the posterior capsule and anterior vitreous, and IOL implantation.  Table 1 demonstrates that 
there has been a wide range of approaches to these controversies in retinoblastoma patients.  
Our group, Miller et al. (2005) reported good visual and anatomic results in 16 patients after 
ECCE/PPV/PCIOL.  Payne et al. (2008) also reported good results with an ECCE approach 
with a capsulotomy, anterior vitrectomy, and IOL placed only in some patients.  In contrast, 
Hoehn et al. (2010) reported outstanding results with only a lens aspiration and IOL with no 
posterior capsulotomy, deferring this procedure to a later EUA when needed.   
The major concern for patients undergoing any intraocular procedure who have a history of 
retinoblastoma is tumor recurrence or the development of metastatic disease as a result of the 
surgery.  Recurrences have been reported in series by Brooks et al. (1990), Honovar et al. 
(2005), Moshfeghi et al. (2005), and Osman et al. (2011).  All of these series included patients 
who had short quiescent intervals from the time of attainment of local control of the 
retinoblastoma and cataract surgery, sometimes as short as 3 months.  It seems that a longer 
quiescent interval is the only identifiable risk factor for this devastating complication.  In 
patients with a short quiescent interval whose fundus cannot be visualized due to a dense 
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cataract, we strongly recommend enucleation rather than performing cataract surgery with its 
associated risk of tumor recurrence which may or may not be able to be adequately treated.  
 
Author, Year 
No. of 
eyes 
Median 
Quiescent 
interval 
(Range)
Procedure 
(No. of eyes)
Median 
follow up, 
mos 
(range)
No. of 
RB 
recur-
ences
Visual outcome 
(No. of eyes) 
Monge et al., 
1986 
2 
30 mos (72 
mos)
Asp ± PPV (24-78) 0 6/18 (2) 
Brooks et al., 
1990 
42 
29 mos (17-
144)
Asp or PPL  72 (6-178) 3 
20/20-20/50 (19) 
20/80-CF (12) 
Portellos & 
Buckley, 1998 
11 
55 mos (16-
88) 
ECCE + 
caps+Ant Vtx 
+ PCIOL
Mean 20 
(6-39 
0 
20/20-20/30 (6)  
20/50-20/250 (5) 
Madreperla et 
al., 2000 
3 
34 mos (9-40 
mos)
Asp (60-189) 0 20/60 (2); HM (1) 
Bhattacharjee et 
al., 2003 
1 84 mos 
ECCE+Caps+
PCIOL
144 0 20/30 
Shanmugam et 
al., 2004 
5 
Minimum 24 
mos 
Phaco+caps+
Ant 
Vtx+PCIOL
NA 0 >6/9 (4) at 6 wks 
Sinha et al., 2004 9 
Minimum 12 
mos
Asp (24-42) 0 “No improvement” 
Miller et al., 2005 16 
Minimum 18 
mos
ECCE+PPV+P
CIOL
Mean 66 
(30-94)
0 
20/20-20/40 (11) 
20/200-20/400 (5) 
Honovar et al., 
2005 
34 
16 mos (3-54 
mos)
ICCE; ECCE; 
PPL
72 (12-360) 5 >20/200 (12) 
Moshfeghi et al., 
2005 
4 
89 mos (12-
172 mos)
NA 
Mean 184 
(60-339)
1 
20/30; CF; HM; 
Enuc
Payne et al., 2008 12 
35 mos (17-
240) 
ECCE ± caps 
± Ant Vtx ± 
PCIOL 
72 (13-148) 0 
20/20-20/60 (6) 
20/70-20/200 (2) 
CF (2) 
HM (2) 
Hoehn et al., 
2010 
19 NA Asp + IOL 
Mean 58 
(19-105) 
0 
20/20-20/60 (3) 
20/70-20/200 (4) 
20/400 (4) 
CF (5) 
HM (1) 
F+F (1) 
Enuc (1) 
Osman et al., 
2011 
21 
21.5 ms (3-
164 mos) 
ECCE or Asp 
± caps ± Ant 
Vtx ± IOL 
Mean 90 ± 
69 
3 
20/20 (4) 
20/20-20/200 (9) 
<20/200 (2) 
NLP (3) 
NA (3) 
Table 1. Reports of cataract surgery in patients with a history of retinoblastoma.  Modified 
and adapted from Payne et al. (2009). NA, Data not reported; Ant Vtx, anterior vitrectomy; 
ECCE, extracapsular cataract extraction; ICCE, intracapsular cataract extraction; IOL, 
posterior chamber intraocular lens; Phaco, phacoemulsification; PPL, pars plana lensectomy; 
NLP, no light perception; HM, hand motion; CF, count fingers. 
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3. Cataracts in uveal melanoma patients  
3.1 Epidemiology 
3.1.1 Incidence 
There have been several studies examining the incidence and risk factors for the 
development of cataracts after Iodine 125 brachytherapy, the most commonly employed 
treatment for uveal melanoma in the United States (Table 1).  Taking these studies as a 
group, approximately 40% of all patients have been reported to develop cataracts with most 
studies having a follow-up period of 5 years.  Among these studies, however, the 
Collaborative Ocular Melanoma Study trial was the only prospective, multicenter trial and 
the rate of cataract development in this study was much higher, 83% by 5 years.  
 
Author, Year 
No. of 
patients at 
risk/No. of 
cataracts 
Rate of cataract 
development 
Follow-up 
time Median 
(Range) 
Time to 
cataract 
development 
Median 
(Range)
Risk factors for 
cataract 
development 
Garretson  
et al., 1987 
26/3 NA 
Mean 45 mos 
( 2 yrs) NA NA 
Bosworth  
et al., 1988 
58/13 NA 
Mean 48.7 
(23-112)
NA NA 
Lean  
et al., 1990 
56/20 NA 
Mean 39 mos 
(20-57)
NA NA 
Mameghan  
et al., 1992 
53/4 NA NA NA NA 
Quivey  
et al., 1993 
239/33 25-50% by 5 yrs NA, (2-10 yrs) 9-81 mos NA 
Shields  
et al., 2002 
270/NA 
2% at 2 yrs, 6% at 
5 yrs
NA NA NA 
Bechrakis  
et al., 2002 
152/5 28%  33 mos NA NA 
Fontanesi  
et al., 1993 
144/43 NA 
46 mos (25-
90)
3-53 mos Tumor location 
Puusari  
et al., 2004 
96/65 2% by 2 yrs NA Median 18 mos
Dose to lens, 
age, diabetes 
Puusari  
et al., 2004 
89/57 69% by 3 yrs 
3.5 yrs (0.3-
10.4)
<1-8 yrs NA 
Lumbroso-Le 
Rouic  
et al., 2004 
NA 
21% by 2 yrs, 50% 
by 5 yrs 
NA NA 
Gender, age, 
diameter 
Stack  
et al., 2005 
92/9 11% 31 mos (4-86) NA NA 
COMS, 2007 538/362 83% by 5 yrs 
NA (data not 
provided in 
this format)
2.5 yrs (6 mos-5 
yrs) 
Age, Baseline 
tumor size, 
Dose to lens 
Meta-analysis 1543/614 40% – – –
Table 2.  Rates of Cataract Development after Cataract from Iodine 125 Brachytherapy for 
Uveal Melanoma.  Updated and Adapted from Collaborative Ocular Melanoma Study 
Group (2007).  NA, Data not reported. 
 
Cataract Surgery in Patients with a History of Retinoblastoma and Melanoma 
 
395 
3.1.2 Risk factors 
The number of studies reporting risk factors for cataract development after Iodine 125 
brachytherapy is limited.  Overall, a review of the literature indicates that cataractogenesis is 
likely a function of tumor size, tumor location, radiation dose, and patient age.  There 
appears to be no obvious advantage to any particular form of radiation (i.e. Cobalt 60, 
Ruthenium 106, proton beam therapy) (Collaborative Ocular Melanoma Study, 2007).  
3.2 Visual and anatomic results  
3.2.1 Visual results 
Several studies have reported on visual acuity results after cataract surgery.  In the 
Collaborative Ocular Melanoma Study, in patients with medium-sized tumors undergoing 
cataract surgery, the median best corrected visual acuity at baseline was 20/25 
(Collaborative Ocular Melanoma Study Group, 2007).  In the group that underwent cataract 
surgery, the median visual acuity before surgery was 20/125 (range 20/25< 20/1600) and 
median visual acuity at the study visit immediately after cataract surgery was 20/50 (range 
20/20-20/1600).  In the study, 32 of the 48 eyes (66%) had improved vision of greater than or 
equal to 2 lines, 13 eyes (27%) remained stable, and 3 (6%) had decreased vision of greater 
than or equal to 2 lines at final follow-up.  Figure 1 demonstrates the change in visual acuity 
in the 3 months after cataract surgery in patients in the Collaborative Ocular Melanoma 
Study. 
 
 
Fig. 1. Patients’ visual acuity before and in the 3 visits after cataract surgery in the 
Collaborative Ocular Melanoma Study.  The dot represents the mean of the box and the 
range of the box extends from the 25th percentile to the 75th percentile.  The whiskers extend 
up to 1.5 times with interquartile range from each end of the box.  Reproduced with 
permission from Collaborative Ocular Melanoma Study (2007). 
Our group investigated visual acuity outcomes in patients undergoing cataract surgery with 
injection of intravitreal triamcinolone injection (Cebulla et al., 2008).  In this study, 51 eyes of 
49 patients with a history of choroidal nevi or uveal melanoma underwent cataract surgery 
with injection of intravitreal triamcinolone (IVTA) during surgery.  There were 30 patients 
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who had had a history of melanoma treated with Iodine-125 brachytherapy in the cohort.  
Among the melanoma patients, the visual acuity at 6 months after surgery was worse in 2 
patients (11%), stable in 2 patients (11%), and better in 14 patients (78%).  At the final follow-
up, vision was worse in 3 patients (10%), stable in 7 patients (24%), and better in 19 patients 
(66%).  The mean number of Snellen lines gained after surgery was 3.9  3.8 (SD) at 6 months 
and 3.1  3.8 at last follow up (both p<0.001).  This data compares favorably to the data 
outlined above and from Gragoudas et al. (1992), the largest study published to date in 
patients undergoing proton beam radiotherapy (Figures 2A-2G). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2A. Patient with uveal melanoma at the time of diagnosis.  Visual acuity was 20/40. 
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Fig. 2B. Photo of tumor apex of patient in Figure 2A at diagnosis.  
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Fig. 2C. Patient in Figure 2A, 21 months after diagnosis.  Note the yellow hue of the 
photograph and inability to visual the macula and optic nerve well to assess radiation 
retinopathy.  The vision was 20/80.  The patient subsequently underwent cataract surgery 
with intravitreal triamcinolone acetonide. 
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Fig. 2D. Patient in Figure 2C after cataract surgery.  Note the increased ability to visualize 
the macula and optic nerve.  The patient’s best corrected vision improved to 20/60. 
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Fig. 2E. B-scan ultrasound of the tumor in Figure 2A at diagnosis with an apical height of  
7.5 mm. 
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Fig. 2F. B-scan ultrasound of the tumor in Figure 2E after plaque surgery just before cataract 
surgery with an apical height of 5.8 mm. 
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Fig. 2G. B-scan ultrasound of the tumor in Figure 2E eight months after cataract surgery.  
The tumor’s apical height has decreased further to 5.6 mm. 
3.2.2 Anatomic outcomes 
The study by our group published in 2008 is the only study to our knowledge which has 
addressed the issue of anatomic changes induced in the treated melanoma as a result of 
cataract surgery (Cebulla et al., 2008).  In this study, cataract surgery was combined with 
intravitreal triamcinolone (IVTA) at the time of surgery.  Triamcinolone was chosen 
because it has been demonstrated to inhibit angiogenesis and to have direct 
antineoplastic activity (DiSorbo et al., 1986; Ebrahem et al., 2006).  Furthermore, 
triamcinolone acetonide has been used to decrease radiation retinopathy and optic 
neuropathy in eyes with uveal melanoma treated with plaque therapy (Shields et al., 
2006).  In the study, echographic measurements of patients’ tumors were followed in 
melanoma patients after cataract surgery-IVTA. This analysis demonstrated that 12 (46%) 
of 26 melanomas diminished in size over a median follow-up period of 11.8 months 
(range, 1-26 months).  Regression analysis demonstrated a shallow but statistically 
significant (p=0.039) negative slope in tumor height after cataract surgery-IVTA.  Tumor 
growth did not occur in any patients.  It was difficult to determine if this effect was due 
to a continuing effect from previous brachytherapy, although the median interval 
between plaque therapy and cataract surgery was 34 months (range 7-114 months), and 
the majority of the decrease in tumor height typically occurs within the first 2.5 years of 
tumor treatment.  Ultimately, in long-term follow-up, the rate of tumor recurrence in this 
population may be lower than the published rates of 2.0% to 19.4% (Gragoudas et al., 
1992; Wachtlin et al., 2000) due to the additional antitumoral effect from the IVTA 
approach. Further prospective studies are needed to address this question. 
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3.3 Complications  
The complications reported in large studies of patients undergoing cataract surgery after 
plaque therapy for uveal melanoma are listed in Table 3.  
 
Author Complication Incidence 
Cebulla et al., 2008 
Tumor recurrence
Posterior capsular opacity 
Cystoid macular edema 
0 (0%)
8 (27%) 
1 (3%) 
COMS et al., 2007 
Cystoid macular edema
Neovascular glaucoma 
Retinal detachment 
13 (27%)
6 (12%) 
1 (2%) 
Wachtlin et al., 2000 
Enucleation required for tumor 
recurrence, scleral necrosis, or pain 
Dislocated IOL 
Posterior capsular opacity 
Vitreous hemorrhage 
Retinal detachment 
7 (10%)
 
1 (1.4%) 
8 (11%) 
4 (6%) 
2 (3%) 
Gragoudas et al., 
1992 
Tumor recurrence 
Retinal detachment 
Vitreous hemorrhage 
Chronic wound leak  
Neovascular glaucoma 
Enucleation for retinal detachment, 
neovascular glaucoma, pain, tumor 
recurrence 
2 (3%) 
2 (3%) 
1 (1%) 
1 (1%) 
3 (4%) 
5 (6%) 
Table 3. Complications observed after cataract surgery in patients with a history of uveal 
melanoma after plaque brachytherapy or proton beam radiotherapy. 
Complication profiles seem to have improved over the past 20 years, likely due to the 
modernization of phacoemulsification techniques such as small incisions, and of the more 
judicious use of cataract surgery, reserving the procedure only for patients with 
preoperative visual potential and no pre-existing neovascular glaucoma secondary to 
radiation vasculopathy.  
4. Conclusion 
In summary, cataract surgery has been safely performed in patients with a history of both 
retinoblastoma and melanoma.  Controversy still exists regarding the best technique in patients 
with a history of retinoblastoma, but we have had success with no tumor recurrences in a series 
of patients with long-term follow-up using a ECCE/PPV/IOL approach.  Tumor recurrence is a 
known risk of this surgery, and patients should demonstrate a quiescent interval of at least 18 
months before surgery.  Visual results are largely dependent on side effects from the primary 
tumor.  In uveal melanoma patients, cataracts are common after plaque therapy and occur on 
average 2.5 years after initial treatment.  Most patients regain vision and vision is typically 
limited by radiation retinopathy, cystoid macular edema, and neovascular glaucoma.  Surgical 
adjuncts such as IVTA may help in decreasing the inflammatory nature of these tumors and 
contribute to tumor regression.  Further prospective studies are needed. 
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